Today: 28 February 2026
Subscribe
Browse Category

NASDAQ:OMER 15 October 2025 - 25 December 2025

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

The FDA approved Omeros’ Yartemlea (narsoplimab-wuug) for adults and children with transplant-associated thrombotic microangiopathy, marking the first approved therapy for this condition. Omeros shares surged to a 52-week high after trading halts and heavy options activity. The company plans a U.S. launch in January 2026. Analysts renewed coverage following the regulatory decision.
25 December 2025
Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros (OMER) Stock Surges After Hours on Dec. 24, 2025 After FDA Approves Yartemlea — What to Know Before the Next Market Open

Omeros shares jumped 75% to $15.36 in after-hours trading Wednesday after the FDA approved its first commercial product, YARTEMLEA, for a rare post-transplant complication. The stock saw heavy volume and a wide range, with multiple trading halts reported. U.S. markets closed early for Christmas Eve and will reopen Friday. The FDA had previously rejected the drug in 2021.
24 December 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares soared 150% to $10.42 on Oct. 15 after Novo Nordisk agreed to license its drug zaltenibart (OMS906) for $340 million upfront and up to $2.1 billion in milestones and royalties. Trading volume hit 89.2 million shares, far above average. Omeros reported a Q2 net loss of $25.4 million and $28.7 million in cash as of June 30. Its lead asset narsoplimab remains under FDA and EMA review.
16 October 2025
···
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Omeros shares soared about 146% on Oct. 15, 2025, closing near $10.11 after Novo Nordisk agreed to license its drug zaltenibart for up to $2.1 billion. Omeros will receive $340 million upfront, with the deal expected to close in Q4. The company will now focus on its lead drug narsoplimab, which is under FDA and EMA review. Analyst targets for Omeros stock range from $9 to $36.
15 October 2025
···
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know

Novo Nordisk will pay up to $2.1 billion to license Omeros’s experimental MASP-3 inhibitor zaltenibart for rare blood and kidney disorders. Omeros receives $340 million upfront, with additional milestone and royalty payments possible. Omeros shares jumped about 65% on the news, while Novo’s stock fell 1.5%. The deal is expected to close by Q4 2025.
15 October 2025
···
Go toTop